论文部分内容阅读
为研究 Ｉ Ｌ－ ２ Ｒα链单抗（ａ Ｉ Ｌ－ ２ Ｒα Ｍ Ａｂ）及肿瘤活化的杀伤细胞（ Ａ Ｋ 细胞）治疗对肝癌细胞致瘤性的影响，将近交系 Ｂａｌｂ／ｃ 小鼠随机分成５ 组，每组８ 只，分别给予 Ｈａｎｋｓ 液， Ｉ Ｌ－ ２，ａ Ｉ Ｌ－ ２ Ｒα Ｍ Ａｂ 及 Ａ Ｋ 细胞治疗，于治疗后第８ 天将 Ｈ２２肝癌细胞接种于 Ｂａｌｂ／ｃ 小鼠皮下，以观察肿瘤结节的发生率，肿瘤的潜伏期及肿瘤结节的体积和重量。结果发现 Ｉ Ｌ－ ２＋ Ａ Ｋ＋ ａ Ｉ Ｌ－２ Ｒα Ｍ Ａｂ 组肿瘤发生率较其它各组有显著差别（ Ｐ＜ ０．０５），肿瘤潜伏期延长，肿瘤结节的生长受到明显抑制，肿瘤重量与其它各组相比均有非常显著差异（ Ｐ＜ ０．０１）。该研究结果表明将 Ｉ Ｌ－ ２， Ａ Ｋ 及ａ Ｉ Ｌ－ ２ Ｒα Ｍ Ａｂ 联合应用可使肝癌细胞致瘤性明显减弱，为临床原发性肝癌病人手术前使用该疗法以减少术后肿瘤的复发和播散提供理论依据。
To investigate the effect of treatment of I L-2 R α chain Ab (a I L-2 R α M Ab) and tumor-activated killer (A K cells) on the tumorigenicity of hepatocellular carcinoma cells, randomized inbred Balb/c mice The rats were divided into 5 groups of 8 mice and were treated with Hanks’ liquid, I L- 2, a I L-2 R α M Ab and A K cells respectively. H22 hepatoma cells were inoculated into Balb/c mice on the 8th day after treatment. Subcutaneously, the incidence of tumor nodules, the latency of tumors, and the volume and weight of tumor nodules were observed. The results showed that the incidence of tumors in the I L- 2+ A K+ a I L-2 Rα M Ab group was significantly different from that in other groups (P < 0.05), the tumor latency was prolonged, and the growth of tumor nodules was significantly inhibited. Compared with other groups, there was a very significant difference (P < 0.01). The results of this study indicate that the combination of I L-2, A K and a I L- 2 R α M Ab can significantly reduce the tumorigenicity of hepatocellular carcinoma. This method is used for the treatment of primary primary liver cancer patients before surgery to reduce postoperative tumors. The recurrence and spread provide theoretical basis.